Safety and Efficacy 31 Week Data of Anavex 2-73 in a Phase 2a Study in Mild-to-Moderate Alzheimer's
- ANAVEX® Life Sciences Corp.
- Nov 11, 2016
- 1 min read
Alzheimer’s Association International Conference 2016, Toronto, Canada
Steve Macfarlane, Marco Cecchi, Dennis Moore, Paul Maruff, Kristina M. Capiak, Christopher U. Missling
